Ulteriori informazioni
Neurodegenerative disorders are rising worldwide, yet most approved drugs merely temper symptoms.
Nucleic Acids and Precision Therapies for Neuroprotection addresses this therapeutic shortfall directly, tracing how antisense oligonucleotides, RNA interference agents, mRNA platforms, aptamers, and CRISPR-class editors are redefining what "treatable" means for Alzheimer's, Parkinson's, ALS, Huntington's disease, and Multiple Sclerosis.
Rather than cataloguing modalities in isolation, the book lays out an end-to-end translational roadmap from target identification and sequence optimisation to blood-brain barrier traversal, immunogenicity management, scalable manufacturing, and ethical oversight. Delivery science (including viral, nanoparticle, and hybrid vectors), AI-enabled biomarker discovery, adaptive trial architectures, and shifting global regulatory frameworks are viewed as interlocking elements of a single development pathway.
By aligning disparate scientific "dialects" into a shared, practice-oriented language,
Nucleic Acids and Precision Therapies for Neuroprotection offers what the field currently lacks: a cohesive guide for moving nucleic acid therapeutics from concept to clinic with precision. Researchers, clinicians, regulators, and industry teams will find pragmatic frameworks, comparative tables, and decision points that shorten the path between mechanistic insight and patient impact without sacrificing rigour or transparency.
Key Features:
¿ Integrates molecular design, delivery engineering, clinical trial strategy, and regulatory science into one end-to-end translational workflow for nucleic acid therapeutics in neurology.
¿ Delivers disease-specific playbooks (AD, PD, ALS, HD, MS) that map genotype/phenotype data to actionable targets, modality selection, and delivery routes.
¿ Embeds AI/ML-driven biomarker discovery, patient stratification, and manufacturability analytics alongside ethical, access, and cost considerations.
Dr. Trideva Sastri Koduru is a pioneer in nanoscience-driven targeted drug delivery and miRNA therapeutics. His research is devoted to advancing nucleic acid therapies through the design of efficient and precise nanocarrier systems, with a strong focus on neurological and autoimmune disorders. Combining expertise in formulation design, bioanalytical validation, and pharmacokinetics, he brings an integrated approach to next-generation drug delivery. His current work emphasizes precision nanocarriers for miRNA delivery, positioning him at the forefront of innovation in drug delivery and neuropharmacology.
Front cover: Depiction of the brain as the central axis of molecular orbits, where nucleic acids and proteins converge to drive next-generation neurological therapies.
Sommario
Foreword
Preface
Acknowledgments
About the Author
Chapter 1 Introduction to Neurodegenerative Disorders
Chapter 2 Traditional Therapies for Neurodegenerative Diseases
Chapter 3 Nucleic Acid Therapies for Neurodegenerative Disorders
Chapter 4 Antisense and RNA-Interference Strategies for Neurodegeneration
Chapter 5 Aptamer and mRNA Platforms for Receptor Targeting and Protein Replacement
Chapter 6 Genome Editing and Next-Generation Nucleic-Acid Tools
Chapter 7 Precision Medicine and Nucleic Acid Therapies for Neurodegenerative Disorders
Chapter8 Challenges in the Development and Application of Nucleic Acid Therapies for
Neurodegenerative Disorders
Chapter 9 Approaches for the Delivery of Nucleic Acid Therapies in Managing Neurodegenerative Disorders
Chapter 10 AI and Nucleic Acid Therapeutics in Neurodegenerative Disease
Chapter 11 Clinical Trials of Nucleic Acid Therapies for Neurodegenerative Disorders
Chapter 12 Regulatory Considerations for Nucleic Acid Therapies in Neurodegenerative Disorders
Chapter 13 Future Perspectives and Challenges in Nucleic Acid Therapies for Neurodegenerative Disorders
Index
Info autore
Dr. Trideva Sastri Koduru is a faculty member in pharmaceutics at JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, India. His PhD work pioneered the use of intranasal nanostructured lipid carriers for miRNA-based modulation of multiple sclerosis, supported by a Senior Research Fellowship from the ICMR's Innovation & Translation Research division. He specialises in nano-carrier platforms for nucleic acid delivery, with a focus on neurological and autoimmune disorders, and brings complementary strengths in formulation design, bioanalytical method validation, and pharmacokinetics. Dr Sastri has strong expertise in miRNA-based drug delivery systems. He has made significant contributions to the pharmaceutical and drug delivery community by publishing several peer-reviewed papers in reputable journals, as well as editing and authoring scholarly chapters and volumes with Academic Press, CRC Press, and Springer. Dr. Sastri's research focuses on nanoscience-aided drug carrier systems and the genetic complexities of autoimmune conditions. His dedication extends to developing efficient carrier systems for delivering nucleic acid therapies, mainly focused on neurological conditions. His forthcoming endeavours centre on crafting highly efficient, targeted carrier systems for delivering miRNA therapeutics, contributing substantially to the progressive landscape of pharmaceutical sciences.
